Teratogenicity and Pregnancy Categories
Certain drugs cause birth defects when used during pregnancy. Understanding teratogenic risk periods, mechanisms, and classification systems guides safer prescribing.
Overview
Teratogenicity refers to the ability of a drug or substance to cause structural or functional abnormalities in a developing embryo or fetus. Approximately 2-3% of birth defects are attributed to drug exposure. Because pregnant women are excluded from most clinical trials, teratogenicity data often comes from animal studies, case reports, and registries.
Critical Periods of Vulnerability
Weeks 1-2 (pre-implantation): The "all-or-none" period. Toxic exposure either destroys the embryo (miscarriage) or is fully repaired by pluripotent cells. Malformations are rare during this period.
Weeks 3-8 (organogenesis): The highest-risk period. Major organ systems are forming, and exposure to teratogens during specific windows causes characteristic malformations. Neural tube closure (weeks 3-4), heart septation (weeks 3-6), and limb formation (weeks 4-8) are particularly vulnerable.
Weeks 9-40 (fetal period): Organs are growing and maturing. Teratogenic exposure primarily affects growth and functional development rather than causing structural malformations. CNS development continues throughout pregnancy, making it vulnerable to neurobehavioral teratogens.
Known Human Teratogens
- Thalidomide: Limb reduction defects (phocomelia). Led to modern drug safety regulations.
- Isotretinoin: Craniofacial, cardiac, and CNS malformations. Requires iPLEDGE program.
- Valproic acid: Neural tube defects (1-2% risk), craniofacial abnormalities, neurodevelopmental impairment.
- Warfarin: Nasal hypoplasia, stippled epiphyses (first trimester). CNS abnormalities (any trimester).
- Methotrexate: Aminopterin syndrome (cranial defects, limb abnormalities). Contraindicated.
- ACE inhibitors/ARBs: Renal agenesis, oligohydramnios, pulmonary hypoplasia (second/third trimester).
- Lithium: Ebstein anomaly (cardiac, though risk lower than initially estimated at ~0.1%).
- Alcohol: Fetal alcohol spectrum disorders (most common preventable cause of intellectual disability).
Classification Systems
The former FDA categories (A, B, C, D, X) were replaced in 2015 by the Pregnancy and Lactation Labeling Rule (PLLR), which provides narrative sections on pregnancy, lactation, and females/males of reproductive potential. The PLLR offers more nuanced risk communication but requires clinical interpretation rather than simple letter grades.
Category X (contraindicated) drugs included isotretinoin, thalidomide, methotrexate, and warfarin. The concept persists in practice even though the letter system is phased out.
Risk Assessment
Teratogenic risk depends on timing, dose, duration, genetic susceptibility, and concurrent exposures. Not all exposures result in malformations. Baseline birth defect rate is 3-5% regardless of drug exposure, which provides important context for risk counseling.
Key Takeaways
- Weeks 3-8 (organogenesis) is the highest-risk period for structural malformations
- Isotretinoin, valproic acid, warfarin, and methotrexate are well-established teratogens
- The PLLR replaced letter categories with narrative risk descriptions in 2015
- ACE inhibitors are safe in the first trimester but contraindicated thereafter
- Pre-conception counseling and medication review are essential for women of childbearing potential